MREO News & Events

Latest data shows the largest indicative borrow rate increases among liquid option names include: T-REX 2X INVERSE MSTR DAILY TARGET (MSTZ) 41.45% +3.39, Kodiak AI, Inc. Common Stock (KDK) 37.84% +2.81, Rani Therapeutics Holdings (RANI) 19.65% +0.48, Direxion Daily 20 plus Year Treasury Bear 3X Shares (TMV) 22.98% +0.45, Mereo BioPharma Group (MREO) 6.43% +0.41, Klarna Group PLC (KLAR) 1.05% +0.30, PureCycle Technologies (PCT) 16.39% +0.29, Takeda Pharmaceutical (TAK) 1.03% +0.29, Richtech Robotics Inc (RR) 1.45% +0.26, and Enbridge (ENB) 0.55% +0.24.

Mereo BioPharma provided an update on its programs, setrusumab for the treatment of osteogenesis imperfecta and alvelestat, which is being studied for the treatment of alpha-1 antitrypsin deficiency-associated lung disease, and revised its cash runway guidance. Data from the Phase 3 Orbit and Cosmic studies of setrusumab in osteogenesis imperfecta, including data on bone mineral density, vertebral fractures, and patient reported outcomes on pain and physical function, will be presented at the J.P. Morgan Healthcare Conference. The Company is also updating its previous cash runway guidance. As of December 31, 2025, cash and cash equivalents were approximately $41 million, which are expected to fund operations to mid-2027. "The reductions and delays in pre-commercial and manufacturing activities related to setrusumab that we implemented following the recent top-line data from the Phase 3 Orbit and Cosmic studies have extended our cash runway to mid-2027 and we will continue to tightly manage our resources as we assess potential next steps for the program, alongside our partner, Ultragenyx," said Dr. Denise Scots-Knight, CEO. "There are no FDA or EMA approved treatments for people living with OI. Although bisphosphonates are used to improve bone mineral density, OI remains a high unmet need. We will continue to assess the totality of the Phase 3 trial data to determine next steps, including potential interactions with the regulators. In parallel, we are advancing partnering discussions for our Phase 3 ready program, alvelestat in AATD-LD."

Latest data shows the largest indicative borrow rate increases among liquid option names include: American Bitcoin Corp (ABTC) 8.00% +3.55, Mereo BioPharma Group (MREO) 5.72% +2.71, DEFIANCE DAILY TARGET 2X LONG RIOT ETF (RIOX) 32.94% +1.15, Star Bulk Carriers (SBLK) 2.26% +0.70, Sealsq Corp (LAES) 55.59% +0.65, Autobot Holdings (ARBE) 6.52% +0.58, Twenty One Capital, Inc. (XXI) 30.44% +0.37, Campbell Soup (CPB) 1.29% +0.27, ProShares UltraShort Lehman 20 plus Year Treasury (TBT) 11.10% +0.26, and United States Oil Fund (USO) 4.52% +0.26.

The major averages closed marginally lower on the penultimate trading day of the year as markets contend with light year-end volumes and a pullback in heavyweight tech and AI names that stalled last week's strong rally. In Fed news, minutes from the latest FOMC meeting show that "most" on the committee have judged that further rate cuts would likely be appropriate if inflation declines over time as expected. In addition, FOMC members have generally judged that upside risks to inflation remained elevated and that downside risks to employment were elevated and had increased since the middle of 2025.Looking to commodities, gold edged higher following yesterday's sharp losses, while oil was fractionally lower ahead of the API crude numbers set for release this afternoon.Get caught up quickly on the top news and calls moving stocks with this Midday Fly By.1. STOCK NEWS:Meta PlatformsAI startup Manus, with the Wall Street Journal reporting that Meta is paying over $2B for the businessApplied Digitalits cloud computing business with Ekso BionicsOn24by Cvent for $8.10 per share in cashCiti'sboard approved a plan toAccording to, "most" on the FOMC have judged that further rate cuts would likely be appropriate if inflation declines over time as expected2. WALL STREET CALLS:ArgusBHP Groupto Buy on "firming" commodity pricesMereo BioPharmato Hold at JefferiesBenchmarkLindblad Expeditionswith a Buy on high growth visibilityStephensof Rubrik, Commvault, and AvePointwith Overweight ratings and Varonisat Equal Weight3. AROUND THE WEB:SMICintends to acquire the remaining 49% stake in unit SMNC for Y40.6B, or $5.79B, giving the company full control of the subsidiary,The U.S. government has granted Samsung Electronicsand SK Hynixan annual license to bring chip manufacturing equipment to their Chinese facilities for 2026,Power-hungry AI projects are benefiting Caterpillaras a range of customers looks to purchase the company's engines and generators,Softbankhas completed its $40B investment in OpenAI,Warner Bros. Discoveryplans to reject Paramount Skydance'sbid next week,4. MOVERS:Hycroft Miningincreases after filing aBoeinggains after being awarded afor the F-15 Israel Program and a ceiling $4.2B modification to a previously awarded Air Force contract for E-4B contractor logistic serviceEnergy Fuelsfalls after Roth Capital said shares of the companyTruth Medialower after Yorkville America launchedon the New York Stock Exchange5. EARNINGS/GUIDANCE:Ree Automotivereported, with EPS higher year-over-yearEtoiles CapitalreportedCemtrexreported, with revenue higher year-over-yearAMTD IDEA Groupreported, with CFO Xavier Zee commenting, "We are proud to deliver another half year of strong performance"INDEXES:The Dow fell 94.87, or 0.20%, to 48,367.06, the Nasdaq lost 55.27, or 0.24%, to 23,419.08, and the S&P 500 declined 9.50, or 0.14%, to 6,896.24.